EHA 2018 | Epigenetic therapies in AML: current and future landscape
Epigenetic therapies are constantly developing in the field of acute myeloid leukemia (AML). In this video, recorded at the 23rd Congress of the European Hematological Association (EHA) 2018, held in Stockholm, Sweden, Andrew Wei, MBBS, PhD, of Monash University, Melbourne, Australia, gives an overview of the current landscape of epigenetic therapies for AML, as well as his predictions for the future directions that this field will take. He discusses the utility of hypomethylating agents, such as decitabine, for patients with TP53 mutations, as well as second generation hypomethylating agents, like guadecitabine, and newer therapies in the clinical setting. Finally, Dr Wei suggests directions for future research, including using next-generation sequencing to identify patients who would benefit from epigenetic therapies earlier in the treatment pathway.
